<DOC> 
<DOCNO>1040624_business_story_3410009.utf8</DOCNO> 
<TEXT> 

The Telegraph - Calcutta : Business
 Thursday, June 24, 2004 				 German firm pays Ranbaxy $4 m
 OUR SPECIAL CORRESPONDENT 																								Mumbai, June 23: Ranbaxy Laboratories Ltd today said it has received $4 million from German pharmaceuticals firm Schwarz Pharma, as milestone payment for progress on the development of RBx 2258  a molecule used for the treatment of benign prostate hyperplasia (BPH).																								Schwarz Pharma completed phase-I clinical trials of the molecule in Europe and is now moving into phase-II trials in Europe and South Africa, Ranbaxy stated in a press release.																								In India, the clinical phase II trial of RBx-2258 is progressing well, the company added.																								In June 2002, Ranbaxy and Schwarz Pharma had signed a licensing deal for Ranbaxys new chemical entity, RBx-2258, for the treatment of BPH. 																								According to the agreement, Schwarz Pharma obtained exclusive rights to develop, market and distribute the product in the US, Japan and Europe, while Ranbaxy retained rights to all other markets. 																								Ranbaxy has already received an upfront payment of $6 million. The agreement also provides for the domestic pharma major to manufacture and supply finished formulations of the product to Schwarz Pharma. 																								The compound is an uro-selective alpha-blocker, which has a patent protection until 2018. It belongs to the latest generation of alpha-blockers for the treatment of BPH. 																								Ranbaxys aim is to develop a once-a-day formulation with rapid relief of symptoms, especially an improved efficacy on lower urinary tract, a low incidence of side effects, good compliance and patient acceptance.																								Schwarz Pharma, headquartered in Monheim, Germany, has a strong international presence with affiliates in the US, Europe and Asia. 
</TEXT> 
</DOC>